234 related articles for article (PubMed ID: 33621416)
21. Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance.
Maiti S; Picard D
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139005
[TBL] [Abstract][Full Text] [Related]
22. Pan-HSP90 ligand binding reveals isoform-specific differences in plasticity and water networks.
Stachowski TR; Nithianantham S; Vanarotti M; Lopez K; Fischer M
Protein Sci; 2023 May; 32(5):e4629. PubMed ID: 36938943
[TBL] [Abstract][Full Text] [Related]
23. Old and New Approaches to Target the Hsp90 Chaperone.
Sanchez J; Carter TR; Cohen MS; Blagg BSJ
Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
[TBL] [Abstract][Full Text] [Related]
24. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
25. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype.
Zanphorlin LM; Alves FR; Ramos CH
Biochim Biophys Acta; 2014 Oct; 1840(10):3145-52. PubMed ID: 24954307
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous Responses and Isoform Compensation the Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer.
Tang X; Chang C; Mosallaei D; Woodley DT; Schönthal AH; Chen M; Li W
Mol Cell Biol; 2022 Feb; 42(2):e0045921. PubMed ID: 34871064
[TBL] [Abstract][Full Text] [Related]
27. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
28. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Peterson LB; Eskew JD; Vielhauer GA; Blagg BS
Mol Pharm; 2012 Jun; 9(6):1841-6. PubMed ID: 22554505
[TBL] [Abstract][Full Text] [Related]
29. GCUNC45 is the first Hsp90 co-chaperone to show alpha/beta isoform specificity.
Chadli A; Felts SJ; Toft DO
J Biol Chem; 2008 Apr; 283(15):9509-12. PubMed ID: 18285346
[TBL] [Abstract][Full Text] [Related]
30. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
Menezes DL; Taverna P; Jensen MR; Abrams T; Stuart D; Yu GK; Duhl D; Machajewski T; Sellers WR; Pryer NK; Gao Z
Mol Cancer Ther; 2012 Mar; 11(3):730-9. PubMed ID: 22246440
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
32. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.
McDowell CL; Bryan Sutton R; Obermann WM
Int J Biol Macromol; 2009 Oct; 45(3):310-4. PubMed ID: 19576239
[TBL] [Abstract][Full Text] [Related]
33. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
Li Y; Zhang T; Schwartz SJ; Sun D
Drug Resist Updat; 2009; 12(1-2):17-27. PubMed ID: 19179103
[TBL] [Abstract][Full Text] [Related]
34. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
35. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
Blagg BS; Kerr TD
Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
[TBL] [Abstract][Full Text] [Related]
36. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal A; Crowley VM; Blagg BSJ
Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
[TBL] [Abstract][Full Text] [Related]
37. An updated patent review of anticancer Hsp90 inhibitors (2013-present).
Li L; Chen NN; You QD; Xu XL
Expert Opin Ther Pat; 2021 Jan; 31(1):67-80. PubMed ID: 32990109
[TBL] [Abstract][Full Text] [Related]
38. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
39. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
40. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
